ESR1 and breast carcinoma: Dual inhibition of estrogen receptors (ERs) and the chaperone protein Hsp90 emerges as a promising therapeutic strategy for the treatment of ER+ breast cancer, particularly in cases of resistance to conventional endocrine therapies.